Literature DB >> 15714495

Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients.

Sophie Vallet1, Stephanie Gouriou, Jean-Baptiste Nousbaum, Marie-Christine Legrand-Quillien, Alain Goudeau, Bertrand Picard.   

Abstract

NS3 protease is essential for hepatitis C Virus (HCV) replication, and is one of the most promising targets for specific anti-HCV therapy. Its natural polymorphism has not been studied at the quasispecies level. In the present work, the genetic heterogeneity of the NS3 protease gene was analyzed in 17 HCV genotype 1 (5 subtypes 1a and 12 subtypes 1b) samples collected from infected patients before anti-viral therapy. A total of 294 clones were sequenced. Although the protease NS3 is considered to be one of the less variable genes in the HCV genome, variability of both nucleotide and amino acid sequences was found. In variants belonging to 1a and 1b subtypes, 224 and 267 of 543 positions showed one or more nucleotide substitutions, respectively. Forty and 74 of the 181 NS3 amino acid positions showed at least one mutation in HCV-1a and HCV-1b isolates, respectively. Most substitutions were conservative. This substantial polymorphism of the NS3 protease produced by HCV-1a and HCV-1b suggests that, despite the numerous functional and structural constraints, the enzyme is sufficiently flexible to tolerate substitutions. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15714495     DOI: 10.1002/jmv.20302

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  A particular hepatitis C virus protease NS3 gene pattern in a patient not responding to interferon-ribavirin therapy.

Authors:  S Vallet; J B Nousbaum; S Gouriou; M C Legrand-Quillien; A Goudeau; B Picard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

2.  The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities.

Authors:  Cihan Aydin; Sourav Mukherjee; Alicia M Hanson; David N Frick; Celia A Schiffer
Journal:  Protein Sci       Date:  2013-10-19       Impact factor: 6.725

Review 3.  Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.

Authors:  Karina Salvatierra; Sabrina Fareleski; Alicia Forcada; F Xavier López-Labrador
Journal:  World J Virol       Date:  2013-02-12

4.  Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.

Authors:  Andrew Bae; Siu-Chi Sun; Xiaoping Qi; Xiaowu Chen; Karin Ku; Angela Worth; Kelly A Wong; Jeanette Harris; Michael D Miller; Hongmei Mo
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

5.  Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.

Authors:  Ingrid Imhof; Peter Simmonds
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

6.  Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.

Authors:  Frederik Pauwels; Wendy Mostmans; Ludo M M Quirynen; Liesbet van der Helm; Carlo W Boutton; Anne-Stéphanie Rueff; Erna Cleiren; Pierre Raboisson; Dominique Surleraux; Origène Nyanguile; Kenneth A Simmen
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

Review 7.  Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.

Authors:  H Le Guillou-Guillemette; S Vallet; C Gaudy-Graffin; C Payan; A Pivert; A Goudeau; F Lunel-Fabiani
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

8.  PoPMuSiC 2.1: a web server for the estimation of protein stability changes upon mutation and sequence optimality.

Authors:  Yves Dehouck; Jean Marc Kwasigroch; Dimitri Gilis; Marianne Rooman
Journal:  BMC Bioinformatics       Date:  2011-05-13       Impact factor: 3.307

9.  New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents.

Authors:  Josep Quer; Maria Buti; Maria Cubero; Jaume Guardia; Rafael Esteban; Juan Ignacio Esteban
Journal:  Infect Drug Resist       Date:  2010-11-23       Impact factor: 4.003

10.  Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.

Authors:  Stefania Paolucci; Loretta Fiorina; Antonio Piralla; Roberto Gulminetti; Stefano Novati; Giorgio Barbarini; Paolo Sacchi; Marta Gatti; Luca Dossena; Fausto Baldanti
Journal:  Virol J       Date:  2012-10-24       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.